Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 5
2004 5
2006 1
2007 5
2008 7
2009 7
2010 8
2011 5
2012 8
2013 2
2014 2
2015 4
2016 6
2017 3
2018 3
2019 1
2020 5
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial.
van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, de Maaker-Berkhof M, Boven E, Schrama J, Geenen MM, Meerum Terwogt JM, van Bochove A, Lustig V, van den Heiligenberg SM, Smorenburg CH, Hellendoorn-van Vreeswijk JA, Sonke GS, Aaronson NK. van Waart H, et al. Among authors: boven e. J Clin Oncol. 2015 Jun 10;33(17):1918-27. doi: 10.1200/JCO.2014.59.1081. Epub 2015 Apr 27. J Clin Oncol. 2015. PMID: 25918291 Clinical Trial.
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y, Hoekman L, Kruger D, Bleijerveld O, Brambillasca CS, Sprengers J, Siteur B, Annunziato S, van Haren MJ, Martin NI, van de Ven M, Peters D, Agami R, Linn SC, Boven E, Altelaar M, Jonkers J, Zingg D, Wessels LFA. Bhin J, et al. Among authors: boven e. J Exp Med. 2023 Nov 6;220(11):e20211743. doi: 10.1084/jem.20211743. Epub 2023 Aug 29. J Exp Med. 2023. PMID: 37642941 Free PMC article.
Beta-glucuronidase-mediated drug release.
de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. de Graaf M, et al. Among authors: boven e. Curr Pharm Des. 2002;8(15):1391-403. doi: 10.2174/1381612023394485. Curr Pharm Des. 2002. PMID: 12052215 Review.
Targeted therapies in renal cell cancer: recent developments in imaging.
van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E. van der Veldt AA, et al. Among authors: boven e. Target Oncol. 2010 Jun;5(2):95-112. doi: 10.1007/s11523-010-0146-5. Epub 2010 Jul 14. Target Oncol. 2010. PMID: 20625845 Free PMC article. Review.
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. Among authors: boven e. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.
Diekstra MHM, Swen JJ, van der Zanden LFM, Vermeulen SH, Boven E, Mathijssen RHJ, Fukunaga K, Mushiroda T, Hongo F, Oosterwijk E, Cambon-Thomsen A, Castellano D, Fritsch A, Donas JG, Rodriguez-Antona C, Ruijtenbeek R, Radu MT, Eisen T, Junker K, Roessler M, Jaehde U, Miki T, Böhringer S, Kubo M, Kiemeney LALM, Guchelaar HJ. Diekstra MHM, et al. Among authors: boven e. Cancers (Basel). 2022 Jun 8;14(12):2838. doi: 10.3390/cancers14122838. Cancers (Basel). 2022. PMID: 35740506 Free PMC article.
A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM. van Hensbergen Y, et al. Among authors: boven e. Biochem Pharmacol. 2002 Mar 1;63(5):897-908. doi: 10.1016/s0006-2952(01)00928-5. Biochem Pharmacol. 2002. PMID: 11911842
80 results